$57.7B of Opioid Settlement Dollars Is Moving Into SUD. Here's What It Means for Operators.

Settlement dollars are landing in state and local government accounts on a schedule that runs through the late 2030s in most jurisdictions. But allocation and deployment are two different things, and the gap between them is wide and uneven.

Kentucky is the starkest example so far: a mid-2026 report from the Kentucky Center for Economic Policy found that 90% of local opioid settlement funds in the state went unspent through the end of fiscal year 2025. Half of local governments there spent zero dollars. Connecticut received $85 million in 2022 and 2023, and $80.5 million of it sat in a bank account, untouched, over that period.

Zoom out to the national data and the pattern holds. KFF Health News, working with Johns Hopkins and the nonprofit Shatterproof, has been tracking settlement spending since the money started flowing. Their most recent analysis found that of the funds tracked, roughly a third had been spent or committed, another third was set aside for future use, and the final third couldn't be tracked at all, because a large number of jurisdictions simply don't produce public reports on how they're using the money.

That last point matters. Reporting requirements vary by state, enforcement is inconsistent, and there's no single body making sure the money gets spent, let alone spent well. Some states are moving fast and building real infrastructure. Others are sitting on growing balances with no clear plan, waiting on legal alignment questions or basic administrative capacity to catch up. If you're trying to read this market by state, "allocated" tells you almost nothing about "deployed," and "deployed" tells you almost nothing about "deployed to where you operate."

Settlement funds are public restitution dollars, not investment capital. That distinction shapes everything about how they behave.

These funds are available once, not an ongoing source. A state's settlement allocation is a fixed pool tied to a legal agreement, not a revenue stream that renews. Once a jurisdiction's share is spent, it's spent. There's no year-two allocation coming behind it the way there is with, say, a Medicaid line item.

Restrictions direct the money toward public health infrastructure, not private operator growth. The funds are meant to support prevention, treatment, recovery, and harm reduction programs, largely through state agencies, counties, and grants to providers and community organizations. They aren't structured as equity, debt, or working capital for an operator trying to open a new site or hire clinical staff ahead of demand. Some of the money eventually reaches operators through grants and contracts. Most of it doesn't touch a P&L directly at all.

Political and administrative processes add risks that traditional capital doesn’t carry. Advisory boards, appropriations processes, and shifting local priorities can all slow the path from an allocation to an actual payment. KFF has also flagged a related concern: as states face Medicaid budget pressure, some officials worry settlement dollars could be used to backfill existing obligations rather than fund new treatment capacity. Attorneys general in several states have pushed back on that possibility, suggesting the risk is more than theoretical.

The money still matters, but it serves a different purpose than the capital operators are usually looking for.

There's one place this money is doing something genuinely useful and specific: covering room and board in residential SUD treatment.

Federal Medicaid law generally prohibits Medicaid from paying for room and board in residential treatment settings. This holds even in states that have used IMD waivers or the 1915(l) state plan option to get Medicaid to cover the clinical services themselves in larger residential facilities. The clinical care can get paid. The bed and the meals can't.

Wisconsin used opioid settlement dollars to close exactly that gap. The state's Department of Health Services awarded grants specifically to cover room and board for Medicaid members in residential OUD treatment, across more than 50 counties and several tribal nations. DHS was direct about why: lack of room-and-board funding is the primary reason Medicaid members don't enroll in residential care at all, even when the clinical benefit is technically covered.

If you’re modeling residential facility economics, this is worth tracking market by market. Settlement money can cover gaps Medicaid reimbursement doesn’t, but it’s still tied to specific costs and levels of care. It can help with one part of the equation, but it won’t fund growth more broadly.

This is where it gets more complicated: waiting on settlement money is a risk when there isn’t much private capital available to fill the gap.

SUD-specific deal volume has been falling for several consecutive quarters. One industry tracker counted 2 addiction treatment deals in Q2 2026, down from 6 in Q1 2026 and 7 in Q2 2025, the lowest quarterly total in its dataset. Two of the sector's largest platforms hit real financial distress this year: Discovery Behavioral Health defaulted on debt and was taken over by its lenders, and BayMark Health Services, one of the largest addiction treatment operators in the country, went through a debt-for-equity restructuring.

Advisors point to the same underlying cause: uncertainty from the One Big Beautiful Bill Act's Medicaid work requirements, most of which don't take effect until 2027, has made buyers and lenders cautious specifically in SUD, even while investment in adjacent behavioral health categories like mental health and ABA has stayed comparatively active.

The two trends point to a tougher capital environment for SUD operators. Settlement dollars are moving slowly and unevenly into public infrastructure. Private capital is pulling back from SUD specifically, for reasons that have nothing to do with settlement funds. Operators counting on either one to solve a near-term capital problem are looking at two sources that are each less reliable right now than they might assume.

Settlement money is worth tracking. It signals where public investment in treatment infrastructure is heading, and in specific cases like residential room and board, it closes a real gap that nothing else does. Follow it market by market, and know what your state and county are actually doing with their allocation, not just what they've been allocated.

But it isn't growth capital, and right now it isn't backstopped by an active private capital market either. If you're planning to expand, add a service line, or get through a lean stretch, the answer isn't "wait for settlement dollars to land" or "assume investors are there when needed." It's making sure your revenue cycle and financial operations are tight enough that you're not dependent on either one showing up on your timeline. Clean claims, faster reimbursement, and accurate documentation are the things you control regardless of what a state opioid settlement board decides to do with its balance this year. If you do need to raise capital, being able to show tight financial operations is what makes you a fundable operator in a market where investors are already being more selective about who they back.

KFF Health News, Payback: Tracking the Opioid Settlement Cash, produced with Johns Hopkins Bloomberg School of Public Health and Shatterproof

Kentucky Center for Economic Policy, Kentucky Local Governments Have Spent Only 10% of Opioid Settlement Dollars Despite Continued Need

CBS News, Millions in Opioid Settlement Funds Sit Untouched as Overdose Deaths Rise

Wisconsin Department of Health Services, Opioids: Settlement Funds

Congressional Research Service, Medicaid’s Institution for Mental Diseases Exclusion

Mertz Taggart, Q2 2026 Behavioral Health M&A Report

Behavioral Health Business, HPS Takes Majority Stake in Discovery Behavioral Health Amid CEO Change

Behavioral Health Business, Why the BayMark Creditor Takeover Casts a Long Shadow on Addiction Treatment Deals